Editas Medicine (EDIT) CEO awarded 1.02M stock options vesting over 4 years

Rhea-AI Filing Summary

Editas Medicine, Inc. reported that CEO O'Neill Gilmore Neil received a grant of stock options covering 1,015,200 shares of common stock at an exercise price of $2.54 per share. The options were granted as compensation and have no purchase price at grant.

The award is scheduled to vest over four years in equal monthly installments, beginning on April 12, 2026 and continuing through March 12, 2030, aligning the CEO’s long-term incentives with company performance over that period.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Neill Gilmore Neil

(Last) (First) (Middle)

C/O EDITAS MEDICINE, INC.

11 HURLEY ST.

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.54	03/12/2026		A		1,015,200		(1)	03/11/2036	Common Stock	1,015,200	$0	1,015,200	D

Explanation of Responses:

1. This option was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments beginning on April 12, 2026 through March 12, 2030.

Remarks:

	/s/ Gilmore O'Neill	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Editas Medicine (EDIT) report for its CEO?

Editas Medicine reported a stock option grant to CEO O'Neill Gilmore Neil for 1,015,200 shares. The options carry a $2.54 exercise price and vest monthly over four years, tying his compensation to Editas Medicine’s long-term stock performance.

How many stock options did the Editas Medicine (EDIT) CEO receive and at what price?

The CEO received stock options for 1,015,200 shares of Editas Medicine common stock at a $2.54 exercise price. The options were granted at no cost and can be exercised at this price once vested over the scheduled four-year period.

What is the vesting schedule for the Editas Medicine (EDIT) CEO’s new stock options?

The stock options granted to the Editas Medicine CEO vest in equal monthly installments over four years. Vesting begins on April 12, 2026 and continues through March 12, 2030, gradually increasing his exercisable ownership stake over time.

Does the Editas Medicine (EDIT) Form 4 indicate an open-market stock purchase or sale by the CEO?

The Form 4 shows a compensation-related stock option grant, not an open-market purchase or sale. The CEO acquired a right to buy 1,015,200 shares at $2.54 per share, subject to monthly vesting from April 2026 through March 2030.

How does this Editas Medicine (EDIT) option grant affect the CEO’s reported holdings?

Following the grant, the CEO’s reported derivative holdings include 1,015,200 stock options tied to Editas Medicine common shares. These options vest monthly over four years, potentially increasing his future equity stake as they become exercisable and are retained.